You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023128012
Dec 202332010
Jan 20242904
Feb 20244005
Mar 20243406
Apr 202410011
May 202420017
Jun 20243406
Jul 202448013
Aug 20241606
Sep 20242205
Oct 20243607
Nov 202441023
Dec 20244609
Jan 202536010
Feb 202512010
Mar 20250015
Apr 2025007
May 20250012
Jun 2025004
Total5840192